Payment overview · 2025
General Payments
$2,467.70
107 reported records · 28 companies
Healthcare provider profile · identity verified
David A Denman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · RINGGOLD, GA · NPI 1942287453
Verified facts
What the public records show
CMS Open Payments records show David A Denman, MD received $2,467.70 in general payments during 2025 across 107 reported records.
ABBVIE INC. accounted for 15.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 48 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Nurtec Odt, Ozempic, Rexulti, Rybelsus, Shingrix, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ubrelvy by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Enbrel by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 386 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 232 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Nurtec Odt by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $388.93 | 15.8% | 15 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $275.86 | 11.2% | 18 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $268.48 | 10.9% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $210.72 | 8.5% | 12 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $142.76 | 5.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $140.03 | 5.7% | 8 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $124.99 | 5.1% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $123.23 | 5.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $81.53 | 3.3% | 5 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $78.45 | 3.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $74.76 | 3.0% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $61.11 | 2.5% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $56.75 | 2.3% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $56.20 | 2.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $53.05 | 2.1% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $51.91 | 2.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $48.69 | 2.0% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $47.95 | 1.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.80 | 1.3% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.25 | 0.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$19.57 | 0.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.14 | 0.7% | 1 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $15.82 | 0.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.36 | 0.6% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $15.36 | 0.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.18 | 0.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.20 | 0.6% | 1 | 2025 |
| Optos, Inc. | Unresolved — no canonical attribution shown | $13.62 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,454.08 | 106 |
| Entertainment | $13.62 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $190.11 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $148.56 | 12 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $146.90 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $142.76 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $138.63 | 10 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $134.33 | 11 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $123.23 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $111.18 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $99.54 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $99.54 | 9 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $88.52 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $88.52 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $88.52 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $88.50 | 5 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $88.50 | 5 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $78.45 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $78.37 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $67.12 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $66.88 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $61.11 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $56.75 | 3 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $56.20 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $53.05 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $51.91 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $51.53 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $47.95 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $47.21 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $37.66 | 2 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $37.10 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $31.33 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.35 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $22.88 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.25 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| NFC-700 Normalized: nfc 700 |
Device | Optos, Inc. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
| OCT OPHTHALMOSCOPE Normalized: oct ophthalmoscope |
Device | Optos, Inc. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
| PANORAMIC OPHTHALMOSCOPE Normalized: panoramic ophthalmoscope |
Device | Optos, Inc. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $3.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 16 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 232 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 76 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 89 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 31 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 386 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 188 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 60 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 16 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 145 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
95 | 28 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
42 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
76 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
16 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
145 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
386 | 62 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
43 | 13 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
188 | 49 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
60 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
232 | 58 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 829 | 234 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 716 | 243 |
| Gabapentin | Gabapentin | 699 | 182 |
| Levothyroxine Sodium | Levothyroxine Sodium | 697 | 185 |
| Amlodipine Besylate | Amlodipine Besylate | 657 | 203 |
| Pantoprazole Sodium | Pantoprazole Sodium | 634 | 205 |
| Omeprazole | Omeprazole | 549 | 168 |
| Carvedilol | Carvedilol | 416 | 128 |
| Metformin Hcl | Metformin Hcl | 411 | 125 |
| Losartan Potassium | Losartan Potassium | 407 | 124 |
| Tramadol Hcl | Tramadol Hcl | 404 | 67 |
| Mounjaro | Tirzepatide | 386 | 62 |
| Lisinopril | Lisinopril | 368 | 111 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 364 | 113 |
| Metoprolol Succinate | Metoprolol Succinate | 364 | 113 |
| Alprazolam | Alprazolam | 340 | 42 |
| Montelukast Sodium | Montelukast Sodium | 333 | 99 |
| Clopidogrel | Clopidogrel Bisulfate | 273 | 88 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 273 | 50 |
| Glimepiride | Glimepiride | 269 | 76 |
| Clonazepam | Clonazepam | 262 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 259 | 86 |
| Potassium Chloride | Potassium Chloride | 258 | 80 |
| Meloxicam | Meloxicam | 255 | 96 |
| Sertraline Hcl | Sertraline Hcl | 252 | 86 |
| Escitalopram Oxalate | Escitalopram Oxalate | 250 | 80 |
| Trazodone Hcl | Trazodone Hcl | 247 | 73 |
| Metformin Hcl Er | Metformin Hcl | 244 | 76 |
| Telmisartan | Telmisartan | 242 | 62 |
| Ondansetron Odt | Ondansetron | 234 | 69 |
| Prednisone | Prednisone | 234 | 105 |
| Eliquis | Apixaban | 232 | 58 |
| Valsartan | Valsartan | 227 | 68 |
| Furosemide | Furosemide | 224 | 79 |
| Ezetimibe | Ezetimibe | 208 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 207 | 60 |
| Simvastatin | Simvastatin | 204 | 52 |
| Ozempic | Semaglutide | 188 | 49 |
| Famotidine | Famotidine | 186 | 61 |
| Allopurinol | Allopurinol | 184 | 62 |
| Torsemide | Torsemide | 180 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 172 | 54 |
| Zolpidem Tartrate | Zolpidem Tartrate | 171 | 55 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 170 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 168 | 51 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 159 | 47 |
| Pioglitazone Hcl | Pioglitazone Hcl | 158 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 157 | 48 |
| Nebivolol Hcl | Nebivolol Hcl | 155 | 47 |
| Fenofibrate | Fenofibrate | 149 | 48 |
| Fluoxetine Hcl | Fluoxetine Hcl | 149 | 53 |
| Doxycycline Hyclate | Doxycycline Hyclate | 148 | 108 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 148 | 46 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 145 | 35 |
| Irbesartan | Irbesartan | 141 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 137 | 54 |
| Ipratropium Bromide | Ipratropium Bromide | 135 | 61 |
| Tresiba Flextouch U-200 | Insulin Degludec | 134 | 42 |
| Chlorthalidone | Chlorthalidone | 131 | 47 |
| Bupropion Xl | Bupropion Hcl | 128 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 121 | 40 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 115 | 39 |
| Promethazine Hcl | Promethazine Hcl | 114 | 30 |
| Buspirone Hcl | Buspirone Hcl | 113 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 113 | 39 |
| Lorazepam | Lorazepam | 109 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 109 | 31 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 108 | 27 |
| Pregabalin | Pregabalin | 106 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 104 | 21 |
| Fluconazole | Fluconazole | 103 | 48 |
| Finasteride | Finasteride | 100 | 35 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 99 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 97 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 96 | 27 |
| Spironolactone | Spironolactone | 96 | 40 |
| Synthroid | Levothyroxine Sodium | 95 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 90 | 19 |
| Jardiance | Empagliflozin | 89 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 86 | 59 |
| Benazepril Hcl | Benazepril Hcl | 85 | 24 |
| Xarelto | Rivaroxaban | 85 | 22 |
| Alendronate Sodium | Alendronate Sodium | 84 | 30 |
| Celecoxib | Celecoxib | 84 | 31 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 84 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 28 |
| Estradiol | Estradiol | 77 | 26 |
| Glyxambi | Empagliflozin/Linagliptin | 77 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 77 | 28 |
| Lovastatin | Lovastatin | 77 | 25 |
| Farxiga | Dapagliflozin Propanediol | 76 | 20 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 73 | 22 |
| Colchicine | Colchicine | 70 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 68 | 18 |
| Gemfibrozil | Gemfibrozil | 67 | 15 |
| Mirtazapine | Mirtazapine | 67 | 19 |
| Nystatin | Nystatin | 67 | 30 |
| Oxycodone Hcl | Oxycodone Hcl | 67 | 15 |
| Entresto | Sacubitril/Valsartan | 66 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 65 | 20 |
| Meclizine Hcl | Meclizine Hcl | 65 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 65 | 26 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 64 | 17 |
| Ibuprofen | Ibuprofen | 64 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 64 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 64 | 21 |
| Atenolol | Atenolol | 63 | 19 |
| Methocarbamol | Methocarbamol | 63 | 17 |
| Solifenacin Succinate | Solifenacin Succinate | 61 | 26 |
| Topiramate | Topiramate | 61 | 14 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 60 | 17 |
| Rybelsus | Semaglutide | 60 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | 22 |
| Ketoconazole | Ketoconazole | 56 | 18 |
| Memantine Hcl | Memantine Hcl | 53 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 52 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 52 | 15 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 52 | 20 |
| Baclofen | Baclofen | 51 | 16 |
| Guanfacine Hcl | Guanfacine Hcl | 50 | 16 |
| Donepezil Hcl | Donepezil Hcl | 48 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 48 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 11 |
| Novolog Flexpen | Insulin Aspart | 47 | 19 |
| Primidone | Primidone | 47 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 35 |
| Clonidine Hcl | Clonidine Hcl | 46 | 18 |
| Fluocinonide | Fluocinonide | 46 | 28 |
| Januvia | Sitagliptin Phosphate | 46 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 46 | 27 |
| Clobetasol Propionate | Clobetasol Propionate | 44 | 28 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 44 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 44 | 15 |
| Tradjenta | Linagliptin | 44 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 43 | 15 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 43 | 14 |
| Trulicity | Dulaglutide | 43 | 13 |
| Myrbetriq | Mirabegron | 42 | 14 |
| Klor-Con M20 | Potassium Chloride | 40 | 13 |
| Lamotrigine | Lamotrigine | 39 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 15 |
| Felodipine Er | Felodipine | 38 | 11 |
| Lansoprazole | Lansoprazole | 38 | 16 |
| Levetiracetam | Levetiracetam | 38 | 11 |
| Nurtec Odt | Rimegepant Sulfate | 37 | suppressed |
| Glipizide | Glipizide | 36 | 11 |
| Nabumetone | Nabumetone | 36 | 18 |
| Valacyclovir | Valacyclovir Hcl | 36 | 17 |
| Amoxicillin | Amoxicillin | 35 | 28 |
| Cefuroxime | Cefuroxime Axetil | 35 | 30 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 26 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | 12 |
| Gemtesa | Vibegron | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 23 |
| Cephalexin | Cephalexin | 31 | 17 |
| Humalog Kwikpen U-200 | Insulin Lispro | 31 | 11 |
| Linzess | Linaclotide | 31 | 14 |
| Ramipril | Ramipril | 31 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 31 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 13 |
| Temazepam | Temazepam | 30 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 29 | suppressed |
| Azithromycin | Azithromycin | 29 | 24 |
| Phenobarbital | Phenobarbital | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | 12 |
| Acyclovir | Acyclovir | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | suppressed |
| Repatha Sureclick | Evolocumab | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 21 |
| Doxepin Hcl | Doxepin Hcl | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 25 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Metronidazole | Metronidazole | 24 | 12 |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 23 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Constulose | Lactulose | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 21 | 13 |
| Nateglinide | Nateglinide | 21 | suppressed |
| Tretinoin | Tretinoin | 21 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 20 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 19 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 14 |
| Fasenra Pen | Benralizumab | 18 | suppressed |
| Lubiprostone | Lubiprostone | 18 | suppressed |
| Clotrimazole | Clotrimazole | 17 | suppressed |
| Minoxidil | Minoxidil | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 16 | 16 |
| Belsomra | Suvorexant | 16 | suppressed |
| Eplerenone | Eplerenone | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 12 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Ubrelvy | Ubrogepant | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 14 | suppressed |
| Humira Pen | Adalimumab | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Cholestyramine Light | Cholestyramine | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Nucynta | Tapentadol Hcl | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Alprazolam Er | Alprazolam | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Enbrel | Etanercept | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Glumetza | Metformin Hcl | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,467.70 · 107 records | ABBVIE INC. | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, CAPLYTA, CAPVAXIVE, COMIRNATY, CREON, DUPIXENT, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FFRct, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, GIMOTI, GVOKE HYPOPEN, INCEPTIV, JARDIANCE, KEVEYIS, Kerendia, LINZESS, MOUNJARO, NFC-700, NURTEC ODT, OCT OPHTHALMOSCOPE, OTEZLA, Ozempic, PANORAMIC OPHTHALMOSCOPE, PREVNAR 20, PROLIA, REPATHA, REXULTI, Rybelsus, SHINGRIX, Symbravo, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error